Versant Capital Management
BCAX icon

Versant Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Versant Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.08K Hold
434
– – ﹤0.01% 2328
2026
Q2 		$12.9K Hold
434
– – ﹤0.01% 2148
2026
Q1 		$8.63K Buy
434
+326
+302% +$5.61K ﹤0.01% 2196
2025
Q4 		$1.82K Buy
108
+13
+14% +$222 ﹤0.01% 2460
2025
Q3 		$1.5K Hold
95
– – ﹤0.01% 2456
2025
Q2 		$883 Buy
+95
New +$1.13K ﹤0.01% 2499

Other funds holding BCAX

RTM
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Private Trust Company
Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Versant Capital Management's BCAX Position: Q3 2026 in Review

Versant Capital Management held its Bicara Therapeutics (BCAX) position steady in Q3 2026 at 434 shares worth $8.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2328.

Versant Capital Management first reported a position in BCAX in Q2 2025 and has held it in 6 quarters since. The position peaked at $12.9K in Q2 2026. 10 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

  • Versant Capital Management held 434 shares of Bicara Therapeutics worth $8.08K as of Q3 2026.
  • Versant Capital Management left its Bicara Therapeutics share count unchanged in Q3 2026.
  • Bicara Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2328 holding.
  • Versant Capital Management first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Versant Capital Management's Bicara Therapeutics position peaked at $12.9K in Q2 2026.
  • 10 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.